Hubbs Lab

Translational Neuroscience Center
Boston Children's Hospital · Harvard Medical School

We accelerate the discovery of treatments for neurodevelopmental disorders.

Led by Jed L. Hubbs, PhD, Assistant Professor of Neurology, Harvard Medical School

Research Highlights

From patient-derived neurons to preclinical candidates for rare neurodevelopmental disorders.

Therapeutics for Neurodevelopmental Disorders

Phenotypic screening in patient-derived iPSC neurons to find compounds that rescue disease phenotypes.

iPSC Neurons Phenotypic Screening

Medicinal Chemistry of Natural Product Leads

CBD analog development for non-opioid pain and epilepsy, modulating multiple ion channels involved in pain and seizure signaling with improved drug-like properties.

Medicinal Chemistry Natural Products

RNA-Targeting Therapeutics

Antisense oligonucleotides, small molecules that target RNA splicing, and small molecule-RNA chimeras to upregulate gene expression for haploinsufficiency disorders.

ASOs Splicing Modulators RNA Chimeras

Drug Discovery Tools

Open-access computational tools built by the lab.

Drug Repurposing

AI-powered triage of a 2,975-compound library of FDA-approved drugs and tool compounds against any gene target, with relevance scoring and mechanistic rationale.

Claude Sonnet Tool Compounds

Multi-parameter optimization dashboard with ADMET profiling, on-target activity models, SHAP attribution, and interactive molecular editing.

ADMET-AI MPO SHAP

Virtual Screening

Pick any target and screen roughly 8.4 million in-stock commercial compounds with a machine-learning potency model, calibrated uncertainty, and an emailed ranked hit list.

CATEExpert 8.4M Compounds Conformal

Browse a standalone structure-based screen of 865 protein targets: per-target ranked hits from an 8.4 million compound library, scored by docking and a pose-aware CNN, with the docked pose viewable in 3D.

Uni-Dock gnina 865 Targets

Draw a compound and identify its most likely protein targets by reverse screening across thousands of human targets, with supporting evidence and a confidence-calibrated shortlist.

Reverse Screen ChEMBL

Quick Links

Explore the lab.

Preclinical Pipeline 15 programs from cohort to preclinical development Publications Selected papers from the lab